Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 22, 2020

Wyatt Technology Launches a New Line of Separation Instrumentation and Software for Analytes

The 6th-generation Eclipse FFF system handles analytes such as proteins, polymers, viruses, gene vectors, and liposomal drug nanoparticles.

On Oct. 20, 2020, Wyatt Technology, a macromolecular and nanoparticle characterization instrumentation company, launched its 6th-generation Eclipse FFF [field-flow fractionation] system, a new line of separation instrumentation and software for analytes such as proteins, polymers, viruses, gene vectors, and liposomal drug nanoparticles.

The new system covers sizes from 1 nm to 10 μm and supplies programable separation power for improved resolution within any size range, a company press release said. The system also features micro-controllers and sensors with built-in intelligence for easy use in quality control environments.

Additionally, the new system comes enabled with Mobility for electrical/asymmetric-flow FFF for determining size-resolved zeta potential, and a Dilution Control Module to increase sample concentrations for higher sensitivity and fraction titer, the press release said.

“The complete execution of a product redesign is difficult enough under ordinary circumstances, but in this case it was re-imagining of what FFF is and how it can be made more accessible to more scientists,” said Geofrey Wyatt, CEO of Wyatt Technology, in the press release. “The resulting products, their novelty and their utility move FFF from a relatively obscure area of separation science into the mainstream.”

Source: Wyatt​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.